
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities and Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 11, 2021

INVITAE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-36847
(Commission
File Number)

27-1701898
(I.R.S. Employer
Identification Number)

1400 16th Street, San Francisco, California 94103
(Address of principal executive offices, including zip code)

(415) 374-7782
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	NVTA	The New York Stock Exchange LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On January 11, 2021, Invitae Corporation (the “Company”) issued a press release announcing preliminary financial results for its fiscal year ended December 31, 2020. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On January 12, 2021, the Company will present at the 39th Annual J.P. Morgan Healthcare Conference using the materials furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by Invitae Corporation dated January 11, 2021.
99.2	Invitae Corporation Corporate Presentation for the 39th Annual J.P. Morgan Healthcare Conference, presented on January 12, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 11, 2021

INVITAE CORPORATION

By: /s/ Thomas R. Brida

Name: Thomas R. Brida

Title: General Counsel



Invitae Reports Preliminary 2020 Financial Results of More Than \$278 Million in Revenue and More Than 655,000 in Billable Volume

— Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific —

SAN FRANCISCO, January 11, 2020 – Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong growth in volume and revenue, signaling continued momentum into 2021.

“We are very pleased by the acceleration of our business in 2020, particularly in light of the impact of the COVID-19 pandemic on the healthcare system throughout the year,” said Sean George, Ph.D., co-founder and chief executive officer of Invitae. “Our results underscore the strength of our customer relationships, our continued ability to execute and the benefits of the investments we’ve made in expanding our menu, services and platform. The growth in testing during this time of unrelenting stress on the healthcare system further demonstrates the expanding value genetic information is providing patients as they and their physicians face health challenges and decisions.”

Preliminary, unaudited financial results and other metrics for 2020

- Generated revenue of more than \$278 million in 2020, an approximate 28% increase from \$217 million in 2019
- Reported billable volume of more than 655,000 in 2020, an approximate 40% increase from billable volume of 469,000 in 2019
- Announced year-end 2020 cash, cash equivalents, restricted cash and marketable securities of more than \$360 million as of December 31, 2020

Outlook for 2021

Looking ahead to 2021 and factoring in the continued impact associated with the COVID-19 pandemic, Invitae reiterates its stated outlook for revenue growth targets of 50% - 60% annual growth over the next few years consistent with its view at the time of the announcement of the ArcherDX acquisition. Invitae anticipates generating revenue in excess of \$450 million in 2021.

“We are confident we will continue growing rapidly in 2021, even as we navigate the continued pressure the pandemic is placing on clinicians,” said Dr. George. “Our momentum coming out of 2020 and the underlying strength and breadth of our platform enable us to recognize and overcome these challenges while continuing to drive the acceleration of the adoption of genetics in mainstream medicine as the new standard of care.”

Invitae has not completed preparation of its financial statements for the fourth quarter or full year 2020. The preliminary, unaudited results presented in this press release for the year ended December 31, 2020 are based on current expectations and are subject to adjustment. Actual results may differ materially from those disclosed in this press release. Invitae will report its full financial results and other metrics during its fourth quarter and year-end 2020 conference call in February.

Invitae's Presentation at 39th Annual J.P. Morgan Healthcare Conference

Invitae will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. Following the company presentation, management will participate in a breakout session at 11:10 a.m. Eastern/8:10 a.m. Pacific. The 2021 J.P. Morgan Healthcare Conference is being held virtually via webinar. A live webcast of both the presentation and the breakout session may be accessed at the following direct link or by visiting the investors section of the company's website at ir.invitae.com. Public listeners can access an audio and slide recording of the session, which will be available shortly after the conclusion of the presentation and breakout session on the investors section of the company's website at ir.invitae.com.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

Safe Harbor Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the company's preliminary financial results for 2020, including billable volume, revenue, cash, cash equivalents, restricted cash and marketable securities; the company's guidance for 2021, including revenue levels; revenue growth targets; the company's beliefs regarding its ability to grow rapidly in 2021; the company's beliefs about its ability to continue to drive the acceleration of the use of genetics throughout mainstream medicine; the company's beliefs about its ability to recognize and overcome certain challenges; the company's beliefs regarding the strength of various attributes of its business that it believes prove a basis for such growth; the company's beliefs regarding the benefits of its acquisitions; and the company's beliefs regarding the momentum in its business and the drivers of such momentum. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: actual results for the fourth quarter and full year 2020, the year-end close process and audit of the company's financial statements; the company's ability to build on

momentum in its business and the drivers of momentum; the impact of the COVID-19 pandemic on the company's business; the company's history of losses; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to compete; the company's ability to develop and commercialize new tests and expand into new markets; risks associated with the company's ability to use rapidly changing genetic data to interpret test results accurately, consistently, and quickly; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's ability to successfully integrate acquired businesses, and the benefits to the company of any such acquisitions; laws and regulations applicable to the company's business; the impact of litigation on the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Source: Invitae Corporation

Contact:

Laura D'Angelo

ir@invitae.com

(628) 213-3369

###



From genetics, health

J.P. Morgan Healthcare Conference

01 | 12 | 21



Safe harbor statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding the shift to universal testing for all, and the timing, value and benefits of such a shift; the company's beliefs regarding its business, including the impact and benefits of its technology, menu, services, platform, team and ecosystem, and its ability to execute; the company's belief regarding the momentum of its business and ability to continue to deliver on its mission to bring genetic information into mainstream medicine; the impact of the company's acquisitions, as well as its internal development efforts, partnerships and product offerings; the company's beliefs regarding the size of various markets and market penetration; the benefits of the company's business strategy; and the company's beliefs regarding its ability to access new and developing markets, improve ease-of-use for customers, and meet the needs of patients and clinicians. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the impact of COVID-19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.



Invitae's mission is to bring
comprehensive genetics into
mainstream medicine to
improve healthcare for
billions of people



INVITAE

© 2021 Invitae Corporation. All Rights Reserved.

Single greatest shift in medicine and healthcare

"Modern" medicine

Chemotherapy standard of care
Newborn diagnosis after birth
Symptom-based, universally applied

Universal testing for all

Risk information = effective prevention
Earliest detection = disease eradication
Personalized therapy and biomarker driven monitoring
Gene-informed healthcare throughout life

Recognizing widespread use of genetics will mean better healthcare for all



Diagnosis and personalized medicine

Incorporating the latest genomic advances into routine healthcare



Prevention

Enabling predictive and preventative care to improve public health and wellness



Research

Supporting research and ensuring a seamless interface between research and healthcare delivery

Moving from testing to information for a lifetime

GENOME MANAGEMENT

Provide genetic information services that inform healthcare throughout life

Share genetics on a global scale to diagnose more patients correctly, earlier, and bring therapies to market faster

GENOME NETWORK

Make acquisitions that expand test menu content and services to open new markets

GENETIC TESTING

Build partnerships with industry peers to increase utilization of genetic testing

Make genetic testing more affordable and more accessible



INVITAE

© 2021 Invitae Corporation. All Rights Reserved.

The pace of adoption is accelerating

GENOME MANAGEMENT

Provide genetic information services that inform healthcare throughout life

Where we are today

Share genetics on a global scale to diagnose more patients correctly, earlier, and bring therapies to market faster

GENOME NETWORK

Make acquisitions that expand test menu content and services to open new markets

GENETIC TESTING

Build partnerships with industry peers to increase utilization of genetic testing


Make genetic testing more affordable and more accessible



INVITAE

© 2021 Invitae Corporation. All Rights Reserved.

The future is closer than you think




We have the technology to enable true personalized medicine today

The right path to accelerate progress



A menu that delivers answers in all stages of life



Enhanced by capabilities beyond content

Menu



Pharmacogenetic testing



Artificial intelligence engine enabling clinical diagnosis from NGS data in minutes



Somatic testing, liquid biopsy and tissue profiling

Services



Clinical decision support tool



Gia chatbot and improved clinic workflow


Platform



Artificial intelligence engine enabling clinical diagnosis from NGS data in minutes



An ecosystem to deliver better outcomes



Serving large addressable markets

**\$26
billion**

Total opportunity
for genetic testing
ages 0-17

- Newborn Screening
- Developmental Delay
- Diagnosis/Prognosis

**\$5
billion**

Total opportunity
for genetic testing
ages 18-40

- Conception
- Assisted Repro/IVF
- Pregnancy/Perinatal

**\$60
billion**

Total opportunity
for genetic testing
ages 41-65

- Risk/Screening
- Familial Risk
- Diagnostic

**\$63
billion**

Total opportunity for
genetic testing
ages 65+

- Screening/Germline
- Oncology Therapy Selection
- MRD/Recurrence Monitoring



INVITAE

© 2021 Invitae Corporation. All Rights Reserved.

* Based on internal Invitae estimates and external sources (2021).
Testing categories assigned to peak incidence age groups.

13


Delivering a lifetime of
better health for **billions**
of people worldwide



INVITAE


© 2021 Invitae Corporation. All Rights Reserved.

A strategy built for growth



Consistent execution as we scale*

Volume



Revenue



*Depicts quarterly results for the past five years; for 2020, results are preliminary, unaudited

Right time, right plan, right team

Disruptive platform
transforming genetics
into better health

Ecosystem that drives
better outcomes for all

Proven leader driving
high growth and
industry impact

**...and we are just
getting started.**

Join us.



INVITAE

© 2021 Invitae Corporation. All Rights Reserved.



INVITAE